Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 1, 1997

View Archived Issues

Hyalgan introduced in U.S. for osteoarthritis of the knee

First approval for irbesartan

Shire acquires Richwood

North American clinical trials with LiquiVent to be reinitiated

ArQule and GenQuest cancer collaboration

NDA for Colazide accepted for review by FDA

FDA clears new formulation of Imitrex

FDA requests additional manufacturing data before approval of Rituxan

Small peptides developed at Prolifix induce apoptosis in cancer cells

LU-51198 prevents complement-mediated myocardial injury

What's new in Cardiology? Highlights from the 19th Congress of the European Society of Cardiology

Famotidine for schizophrenia

Migraine prophylaxis with bisoprolol

Soluble TNF receptor may benefit patients with coronary artery disease

Cardiovascular benefits of the Mediterranean diet

Past, present and future of arrhythmia therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...